Marco DiBonaventura

机构：Pfizer (United States) · ORCID：0000-0002-8333-4676

发表论文 332 篇 · 总被引 10310 次 · h-index 50

代表论文

Elranatamab efficacy in MagnetisMM-3 compared with real-world control arms in triple-class refractory multiple myeloma (2024 · Future Oncology · 被引 17)
Impact of elranatamab on quality of life: Patient‐reported outcomes from MagnetisMM ‐3 (2024 · British Journal of Haematology · 被引 13)
The impact of reduced dosing frequency of elranatamab on patient‐reported outcomes in patients with relapsed or refractory multiple myeloma: Results from MagnetisMM‐3 (2025 · HemaSphere · 被引 3)
Comparison of Patient-Reported Outcomes for Elranatamab in MagnetisMM-3 Versus Real-World Physician Choice of Therapy for Triple-Class Refractory Multiple Myeloma (2026 · Clinical Lymphoma Myeloma & Leukemia · 被引 2)
An Updated Indirect Comparison of Elranatamab Versus a Real-World External Control Arm in Triple-Class Refractory Multiple Myeloma (2025 · Blood and Lymphatic Cancer Targets and Therapy · 被引 2)
The Effect of Elranatamab on Patient-Reported Outcomes in Patients with Relapsed/Refractory Multiple Myeloma Naïve and Exposed to B-Cell Maturation Antigen (BCMA)-Directed Therapies: Updated Follow-Up from the MagnetisMM-3 Study (2024 · Blood · 被引 2)